Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment reporting

Analytics

Phase 2
7(87.5%)
Phase 3
1(12.5%)
8Total
Phase 2(7)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
SYF22d858c94f4e4514b1a62b1f28b9e671Phase 2Recruiting

Clinical Trial on PREnatal Dexamethasone In Congenital adrenal hyperplasia Therapy - PREDICT -

Role: lead

SYF2897d056177d438d8b6666635b09b122Phase 2Suspended

Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia - A prospective two-armed, phase II clinical multicentre randomized, placebo-controlled (2:1), blinded with open-label extension trial (TEFIBEOS)

Role: lead

SYF2ab9dcf726484a8cb936d9952151b3e4Phase 2Not Yet Recruiting

Investigation of breathable surfactant agent in patients with idiopathic lung fibrosis

Role: lead

SYF53f5e2ab357f452c9ac91ed0009cf25cPhase 2Suspended

Proof-of-concept study of Empagliflozin in patients with pulmonary arterial hypertension (EmPAH)

Role: lead

SYF884e97cc126a4a92a4d2678ad996e6f5Phase 2Not Yet Recruiting

Study of safety and tolerability following administration of metformin in patients with idiopathic pulmonary fibrosis (IPF)

Role: lead

SYF96e57766bfab46f7ba47cdba66d8a9a7Phase 2Recruiting

Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II study (TAILOR-CSU)

Role: lead

SYFaf8775898b6d45e8ac8db3618eaebb24Phase 3Recruiting

Adjuvant radioligand therapy in neuroendocrine tumors

Role: lead

SYFcda61230d85344cbb31141bd5f67659ePhase 2Recruiting

Inhalation therapy in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept - randomized controlled trial

Role: lead

All 8 trials loaded